Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) EBIT (2022 - 2025)

Historic EBIT for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $43.0 million.

  • Indivior Pharmaceuticals' EBIT rose 2285.71% to $43.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.0 million, marking a year-over-year increase of 44047.62%. This contributed to the annual value of $38.0 million for FY2024, which is 105000.0% up from last year.
  • Latest data reveals that Indivior Pharmaceuticals reported EBIT of $43.0 million as of Q3 2025, which was up 2285.71% from $72.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' EBIT registered a high of $72.0 million during Q2 2025, and its lowest value of -$258.0 million during Q4 2022.
  • Moreover, its 4-year median value for EBIT was $56.5 million (2022), whereas its average is $4.6 million.
  • In the last 5 years, Indivior Pharmaceuticals' EBIT crashed by 42678.57% in 2023 and then surged by 16101.69% in 2025.
  • Quarter analysis of 4 years shows Indivior Pharmaceuticals' EBIT stood at -$258.0 million in 2022, then soared by 123.26% to $60.0 million in 2023, then fell by 23.33% to $46.0 million in 2024, then decreased by 6.52% to $43.0 million in 2025.
  • Its last three reported values are $43.0 million in Q3 2025, $72.0 million for Q2 2025, and $66.0 million during Q1 2025.